Results 11 to 20 of about 22,201 (271)

Corrigendum: Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system [PDF]

Drugs in Context, 2023
The authors wish to make the following corrections to their article: Mannaioni G, Lugoboni F. Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on ...
Guido Mannaioni, Fabio Lugoboni
doaj   +3 more sources

Healthy eating among people on opioid agonist therapy: a qualitative study of patients’ experiences and perspectives [PDF]

BMC Nutrition
People with substance use disorders often have unhealthy diets, high in sweets and processed foods but low in nutritious items like fruits and vegetables, increasing noncommunicable disease risks.
Einar Furulund, Karl Trygve Druckrey-Fiskaaen, Siv-Elin Leirvåg Carlsen, Tesfaye Madebo, Lars T. Fadnes, Torgeir Gilje Lid   +5 more
doaj   +3 more sources

Integrated exercise program in opioid agonist therapy clinics and effect on psychological distress: study protocol for a randomized controlled trial (BAReAktiv) [PDF]

Trials
Background Substance use disorder is associated with unhealthy lifestyle choices, resulting in adverse social and health consequences. People with opioid use disorder receiving opioid agonist therapy, in particular, have high morbidity and reduced ...
Einar Furulund, Tesfaye Madebo, Karl Trygve Druckrey-Fiskaaen, Jørn Henrik Vold, Mette Hegland Nordbotn, Eivin Dahl, Sindre M. Dyrstad, Torgeir Gilje Lid, Lars T. Fadnes, for the ATLAS4LAR study group   +9 more
doaj   +3 more sources

Evaluating the Impact of Increased Dispensing of Opioid Agonist Therapy Take-Home Doses on Treatment Retention and Opioid-Related Harm among Opioid Agonist Therapy Recipients: A Simulation Study

Systems, 2023
Modified opioid agonist therapy (OAT) guidelines that were initially introduced during the COVID-19 pandemic allow prescribers to increase the number of take-home doses to fulfill their need for physical distancing and prevent treatment discontinuation ...
Narjes Shojaati, Nathaniel D. Osgood
doaj   +3 more sources

Comparing Canadian and United States opioid agonist therapy policies

International Journal of Drug Policy, 2019
Canada and the United States (U.S.) face an opioid use disorder (OUD) and opioid overdose epidemic. The most effective OUD treatment is opioid agonist therapy (OAT)-buprenorphine (with and without naloxone) and methadone. Although federal approval for OAT occurred decades ago, in both countries, access to and use of OAT is low. Restrictive policies and
Kelsey C Priest, Lauren Gorfinkel, Jan Klimas   +2 more
exaly   +5 more sources

Retention in Opioid Agonist Therapy Among First Nations People.

JAMA Netw Open
ImportanceFirst Nations people are disproportionately impacted by the opioid crisis in Canada. While many First Nation communities have expanded access to treatment, there is a need to better understand the factors associated with early discontinuation of opioid agonist therapies (OAT).ObjectiveTo investigate factors associated with OAT retention ...
Holton A, Hamzat B, McCormack D, Bragg S, deGonzague B, Mecredy G, Campbell T, Antoniou T, McGregor L, Bertram J, Gomes T.   +10 more
europepmc   +4 more sources

Effect of fruit smoothie supplementation on psychological distress among people with substance use disorders receiving opioid agonist therapy: protocol for a randomised controlled trial (FruktBAR) [PDF]

BMC Nutrition, 2022
Background People with substance use disorders generally have unhealthy diets, including limited intake of fruit and vegetables. Evidence shows substantial health benefits from increasing fruit and vegetable consumption on various indicators and possibly
Lars T. Fadnes, Einar Furulund, Karl Trygve Druckrey-Fiskaaen, Tesfaye Madebo, Jørn Henrik Vold, Maria Olsvold, Marianne Cook Pierron, Siv-Elin Leirvåg Carlsen, Rune Blomhoff, Torgeir Gilje Lid, for the ATLAS4LAR Study Group   +10 more
doaj   +2 more sources

Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review

BMJ Open, 2018
Introduction The opioid crisis has resulted in increasing rates of death caused by problematic opioid use. Current clinical guidelines recommend that individuals with persons with opioid use disorder (OUD) receive pharmacological (eg, opioid agonist ...
Brian Hutton, Beverley Shea, Kimberly Corace, David Moher, Danielle B Rice, Becky Skidmore, Kednapa Thavorn, Sheena Taha, Dianna Wolfe, Fatemeh Yazdi, Beth A Sproule, Melanie Willows, Patricia Poulin, Gary Garber, Amy Porath, Leila Esmaeilisaraji   +15 more
doaj   +2 more sources

High retention in an opioid agonist therapy project in Durban, South Africa: the role of best practice and social cohesion [PDF]

Harm Reduction Journal, 2020
Background Moral conservatism within government and communities has resulted in a reluctance to support the provision of opioid agonist therapy for people with opioid use disorders in South Africa. In April 2017, South Africa’s first low-threshold opioid
Monique Marks, Andrew Scheibe, Shaun Shelly   +2 more
doaj   +2 more sources

Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon

Harm Reduction Journal, 2017
Background Opioid agonist therapy has been widely used to reduce harms among individuals with opioid use disorder but its effectiveness has not been evaluated in the Middle East North African (MENA) region.
Ali Ghaddar, Zeinab Abbas, Ramzi Haddad
doaj   +2 more sources